Novo Nordisk A/S announced a share repurchase program initiated on November 11, 2024, to buy back up to DKK 20 billion worth of shares over 12 months, with DKK 3.1 billion allocated for the period until February 3, 2025. As of November 29, 2024, they had repurchased 21,427,104 B shares valued at DKK 17.77 billion, averaging DKK 829.29 per share.